On Sept. 14, 2021, Emergent BioSolutions announced a five-year contract development and manufacturing (CDMO) services agreement spanning Emergentﾒs integrated capabilities, including development services, bulk drug substance formulation and drug product manufacturing, to support Providenceﾒs COVID-19 messenger RNA (mRNA) vaccine development. In 2022,

Emergent will manufacture tens of millions of doses of PTX-COVID19-B drug product, as well as batches of PTX-COVID19-B formulated bulk drug substance with the potential to yield hundreds of millions more doses, for global populations in need of pandemic relief.